Patent · US Active

Engineered CRISPR-Cas9 nucleases

US10093910B2 · kind B2 · utility

24Cited by

24References

30Claims

0Family size

Assignee

The General Hospital Corporation · US

Inventors

J. Keith Joung · Winchester, US
Benjamin Kleinstiver · Medford, US
Vikram Pattanayak · Wellesley, US

Key dates

Filing date	Dec 5, 2016
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Apr 3, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.